Since we did not detect any significant differences between responsive and refractory patients’ TP53, TET2, IDH2, EZH2 expression, we suggest that the expression of these classically mutated AML genes is not a feature of AML and could not be used for its prognosis. This evidence concerns the gene EZH2 and acute myeloid leukemia.